AMP-activated protein kinase as a target for preconditioning in transplantation medicine

Transplantation

Volumn 90, Issue 4, 2010, Pages 353-358

  Bouma, Hjalmar R ^a   Ketelaar, Marlies E ^a,b   Yard, Benito A ^b   Ploeg, Rutger J ^c   Henning, Robert H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adenosine; AMPK; Ischemia; Preservation; Reperfusion

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE PHOSPHATE; ADENOSINE; ADENOSINE 3' PHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; BIGUANIDE DERIVATIVE; CURCUMIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; METFORMIN; NITRIC OXIDE; PROTEIN KINASE C; PROTEIN KINASE LKB1; PROTEIN TYROSINE KINASE; VASCULAR CELL ADHESION MOLECULE 1;

ANAEROBIC METABOLISM; CELL DEATH; CRYOPRESERVATION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; GRAFT SURVIVAL; HOMEOSTASIS; INFLAMMATION; ISCHEMIC PRECONDITIONING; NONHUMAN; ORGAN PRESERVATION; OSMOREGULATION; PRIORITY JOURNAL; PROTECTION; REPERFUSION; REVIEW; TRANSPLANTATION;

ADENOSINE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CALCIUM; CYTOSOL; ENERGY METABOLISM; GRAFT REJECTION; HUMANS; HYPOXANTHINE; ISCHEMIC PRECONDITIONING; MICE; RECEPTORS, PURINERGIC P1; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SODIUM-POTASSIUM-EXCHANGING ATPASE; TRANSPLANTATION;

EID: 77955983382     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181e7a3aa     Document Type: Review

References (39)

1. McDonald S, Russ G, Campbell S, et al. Kidney transplant rejection in Australia and New Zealand: Relationships between rejection and graft outcome. Am J Transplant 2007; 7: 1201.
2. Barocci S, Valente U, Fontana I, et al. Long-term outcome on kidney retransplantation: A review of 100 cases from a single center. Transplant Proc 2009; 41: 1156.
3. Organ Procurement and Transplantation Network. Available at: http://www.unos.org. Accessed January 4, 2010.
4. Terasaki PI, Gjertson DW, Cecka JM, et al. Fit and match hypothesis for kidney transplantation. Transplantation 1996; 62: 441.
5. Bouma HR, Ploeg RJ, Schuurs TA. Signal transduction pathways involved in brain death-induced renal injury. Am J Transplant 2009; 9: 989.
6. Salahudeen AK. Consequences of cold ischemic injury of kidneys in clinical transplantation. J Investig Med 2004; 52: 296.
7. Brinkkoetter PT, Song H, Losel R, et al. Hypothermic injury: The mitochondrial calcium, ATP and ROS love-hate triangle out of balance. Cell Physiol Biochem 2008; 22: 195.
8. Jassem W, Koo DD, Cerundolo L, et al. Cadaveric versus living-donor livers: Differences in inflammatory markers after transplantation. Transplantation 2003; 76: 1599.
9. Kloner RA, Jennings RB. Consequences of brief ischemia: Stunning, preconditioning, and their clinical implications: Part 2. Circulation 2001; 104: 3158.
10. Peralta C, Bartrons R, Serafin A, et al. Adenosine monophosphate- activated protein kinase mediates the protective effects of ischemic preconditioning on hepatic ischemia-reperfusion injury in the rat. Hepatology 2001; 34: 1164.
11. Sola A, De OJ, Gonzalez R, et al. Protective effect of ischemic preconditioning on cold preservation and reperfusion injury associated with rat intestinal transplantation. Ann Surg 2001; 234: 98.
12. Morrow VA, Foufelle F, Connell JM, et al. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem 2003; 278: 31629.
13. Rakhit RD, Edwards RJ, Marber MS. Nitric oxide, nitrates and isch-aemic preconditioning. Cardiovasc Res 1999; 43: 621.
14. Lochner A, Marais E, Du TE, et al. Nitric oxide triggers classic ischemic preconditioning. Ann N Y Acad Sci 2002; 962: 402.
15. Nandagopal K, Dawson TM, Dawson VL. Critical role for nitric oxide signaling in cardiac and neuronal ischemic preconditioning and tolerance. J Pharmacol Exp Ther2001; 297: 474.
16. Aymerich I, Foufelle F, Ferre P, et al. Extracellular adenosine activates AMP-dependent protein kinase (AMPK). JCellSci 2006; 119: 1612.
17. Bouma MG, Van Den Wildenberg FA, Buurman WA. The anti-inflammatory potential of adenosine in ischemia-reperfusion injury: Established and putative beneficial actions of a retaliatory metabolite. Shock 1997; 8: 313.
18. Peralta C, Hotter G, Closa D, et al. Protective effect of preconditioning on the injury associated to hepatic ischemia-reperfusion in the rat: Role of nitric oxide and adenosine. Hepatology 1997; 25: 934.
19. Ricciardi R, Meyers WC, Schaffer BK, et al. Protein kinase C inhibition abrogates hepatic ischemic preconditioning responses. J Surg Res 2001; 97: 144.
20. Nakano A, Cohen MV, Downey JM. Ischemic preconditioning: From basic mechanisms to clinical applications. Pharmacol Ther 2000; 86:263.
21. Baines CP, Liu GS, Birincioglu M, et al. Ischemic preconditioning depends on interaction between mitochondrial KATP channels and actin cytoskeleton. Am J Physiol 1999; 276: H1361.
22. Morgan EN, Boyle EM Jr, Yun W, et al. An essential role for NF-kappaB in the cardioadaptive response to ischemia. Ann Thorac Surg 1999; 68:377.
23. Xuan YT, Tang XL, Qiu Y, et al. Biphasic response of cardiac NO synthase isoforms to ischemic preconditioning in conscious rabbits. Am J Physiol Heart Circ Physiol 2000; 279: H2360.
24. Heemann UW, Azuma H, Tullius SG, et al. The contribution of reduced functioning mass to chronic kidney allograft dysfunction in rats. Transplantation 1994; 58: 1317.
25. Hardie DG. The AMP-activated protein kinase pathway\New players upstream and downstream. J Cell Sci 2004; 117: 5479.
26. Carling D. AMP-activated protein kinase: Balancing the scales. Bio-chimie 2005; 87: 87.
27. Hardie DG. Minireview: The AMP-activated protein kinase cascade: The key sensor of cellular energy status. Endocrinology 2003; 144:5179.
28. Hattori Y, Suzuki K, Hattori S, et al. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006; 47:1183.
29. Gaskin FS, Kamada K, Yusof M, et al. 5'-AMP-activated protein kinase activation prevents postischemic leukocyte-endothelial cell adhesive interactions. Am JPhysiol Heart Circ Physiol 2007; 292: H326.
30. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 2007; 47: 185.
31. Yu LF, Qiu BY, Nan FJ, et al. AMPK activators as novel therapeutics for type 2 diabetes. Curr Top Med Chem Feb 25, 2010 [Epub ahead of print].
32. Guh JH, Chang WL, Yang J, et al. Development of novel adenosine monophosphate-activated protein kinase activators.J Med Chem 2010; 53: 2552.
33. Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 2010; 1804: 581.
34. Kim T, Davis J, Zhang AJ, et al. Curcumin activates AMPK and suppresses gluconeogenic gene expression in hepatoma cells. Biochem Bio-phys Res Commun 2009; 388: 377.
35. Gruzman A, Babai G, Sasson S. Adenosine monophosphate-activated protein kinase (AMPK) as a new target for antidiabetic drugs: A review on metabolic, pharmacological and chemical considerations. Rev Dia-bet Stud 2009; 6: 13.
36. Lu B, Rajakumar SV, Robson SC, et al. The impact of purinergic signaling on renal ischemia-reperfusion injury. Transplantation 2008; 86: 1707.
37. Zhang J, Kaasik K, Blackburn MR, et al. Constant darkness is a circa-dian metabolic signal in mammals. Nature 2006; 439: 340.
38. Horman S, Hussain N, Dilworth SM, et al. Evaluation of the role of AMP-activated protein kinase and its downstream targets in mammalian hibernation. Comp Biochem Physiol B Biochem Mol Biol 2005; 142: 374.
39. Rider MH, HussainN, HormanS, et al. Stress-induced activation ofthe AMP-activated protein kinase in the freeze-tolerant frog Rana syl-vatica. Cryobiology 2006; 53: 297.